Details
Description
In this report, we assessed utilization of three monoclonal antibody (mAB) drugs within the Sentinel Distributed Database (SDD): lecanemab, aducanumab, and donanemab. We also quantified how often the mABs of interest were used concomitantly with other drugs and drug classes. The study period included data from June 7, 2021 to May 31, 2024.
We distributed this request to six Sentinel Data Partners on January 27, 2025. These six Data Partners are a subset of the SDD. Data from Medicare patients having both fee‐for‐service medical coverage and Part D drug coverage are included.